Investigation of the effect of SGLT-2 inhibitors on the triglyceride/glucose index in diabetic patients: a cross-sectional study

Düriye Sıla Karagöz Özen; Abdulcelil Kayabaş; Rana İlhan Van; Mehmet Derya Demirağ

Makale detayları

Investigation of the effect of SGLT-2 inhibitors on the triglyceride/glucose index in diabetic patients: a cross-sectional study

Yazarlar:

Düriye Sıla Karagöz Özen | Abdulcelil Kayabaş | Rana İlhan Van | Mehmet Derya Demirağ

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Internal Diseases

Dergi:

The European Research Journal Vol.11 Issue 3, pp.449-455

Belge Tipi:

Makale

Yayın Tarihi:

4/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001345449

pISSN:

2149-3189

Anahtar kelimeler:

Özet:

 Objectives: The aim of this study is to estimate the change in the Triglyceride Glucose Index TyG index, in patients with type 2 Diabetes Mellitus who are using a sodium-glucose cotransporter-2 SGLT2 inhibitor, and to evaluate the effect of these drugs on triglyceride glucose index. Methods: This is a cross-sectional study of 55 diabetic patients in our internal medicine clinic in Turkey. Triglyceride, glucose, and glycosylated hemoglobin HbA1c values were measured at the beginning of the treatment and the 3rd-month follow-up. The TyG index of the patients before starting SGLT-2 inhibitor treatment and at the end of 3 months of treatment was calculated by the researchers using the data in the hospital digital records. Results: The mean age of 55 patients 56.4 male was 62.710.2 years. The number of patients using dapagliflozin 10 mg was 15 27.3 and the number of patients using empagliflozin was 41 72.8. It was determined that fasting plasma glucose, TyG index, and HbA1c values before starting SGLT-2 inhibitor treatment and in the 3rd month of treatment decreased significantly P0.001, P0.002 and P0.001, respectively. According to the correlation analysis results between TyG index and HbA1c, it was determined that the values both before treatment and in the 3rd month of treatment showed a correlation r0.516, P0.001 and r0.448, P0.001, respectively. Conclusions: SGLT-2 inhibitor usage significantly reduces TyG index in diabetic patients, and new studies are needed to investigate the effect of these drugs on triglyceride index among pre-diabetic patients.

 Objectives: The aim of this study is to estimate the change in the Triglyceride Glucose Index TyG index, in patients with type 2 Diabetes Mellitus who are using a sodium-glucose cotransporter-2 SGLT2 inhibitor, and to evaluate the effect of these drugs on triglyceride glucose index. Methods: This is a cross-sectional study of 55 diabetic patients in our internal medicine clinic in Turkey. Triglyceride, glucose, and glycosylated hemoglobin HbA1c values were measured at the beginning of the treatment and the 3rd-month follow-up. The TyG index of the patients before starting SGLT-2 inhibitor treatment and at the end of 3 months of treatment was calculated by the researchers using the data in the hospital digital records. Results: The mean age of 55 patients 56.4 male was 62.710.2 years. The number of patients using dapagliflozin 10 mg was 15 27.3 and the number of patients using empagliflozin was 41 72.8. It was determined that fasting plasma glucose, TyG index, and HbA1c values before starting SGLT-2 inhibitor treatment and in the 3rd month of treatment decreased significantly P0.001, P0.002 and P0.001, respectively. According to the correlation analysis results between TyG index and HbA1c, it was determined that the values both before treatment and in the 3rd month of treatment showed a correlation r0.516, P0.001 and r0.448, P0.001, respectively. Conclusions: SGLT-2 inhibitor usage significantly reduces TyG index in diabetic patients, and new studies are needed to investigate the effect of these drugs on triglyceride index among pre-diabetic patients.

 Objectives: The aim of this study is to estimate the change in the Triglyceride Glucose Index TyG index, in patients with type 2 Diabetes Mellitus who are using a sodium-glucose cotransporter-2 SGLT2 inhibitor, and to evaluate the effect of these drugs on triglyceride glucose index. Methods: This is a cross-sectional study of 55 diabetic patients in our internal medicine clinic in Turkey. Triglyceride, glucose, and glycosylated hemoglobin HbA1c values were measured at the beginning of the treatment and the 3rd-month follow-up. The TyG index of the patients before starting SGLT-2 inhibitor treatment and at the end of 3 months of treatment was calculated by the researchers using the data in the hospital digital records. Results: The mean age of 55 patients 56.4 male was 62.710.2 years. The number of patients using dapagliflozin 10 mg was 15 27.3 and the number of patients using empagliflozin was 41 72.8. It was determined that fasting plasma glucose, TyG index, and HbA1c values before starting SGLT-2 inhibitor treatment and in the 3rd month of treatment decreased significantly P0.001, P0.002 and P0.001, respectively. According to the correlation analysis results between TyG index and HbA1c, it was determined that the values both before treatment and in the 3rd month of treatment showed a correlation r0.516, P0.001 and r0.448, P0.001, respectively. Conclusions: SGLT-2 inhibitor usage significantly reduces TyG index in diabetic patients, and new studies are needed to investigate the effect of these drugs on triglyceride index among pre-diabetic patients.

 Objectives: The aim of this study is to estimate the change in the Triglyceride Glucose Index TyG index, in patients with type 2 Diabetes Mellitus who are using a sodium-glucose cotransporter-2 SGLT2 inhibitor, and to evaluate the effect of these drugs on triglyceride glucose index. Methods: This is a cross-sectional study of 55 diabetic patients in our internal medicine clinic in Turkey. Triglyceride, glucose, and glycosylated hemoglobin HbA1c values were measured at the beginning of the treatment and the 3rd-month follow-up. The TyG index of the patients before starting SGLT-2 inhibitor treatment and at the end of 3 months of treatment was calculated by the researchers using the data in the hospital digital records. Results: The mean age of 55 patients 56.4 male was 62.710.2 years. The number of patients using dapagliflozin 10 mg was 15 27.3 and the number of patients using empagliflozin was 41 72.8. It was determined that fasting plasma glucose, TyG index, and HbA1c values before starting SGLT-2 inhibitor treatment and in the 3rd month of treatment decreased significantly P0.001, P0.002 and P0.001, respectively. According to the correlation analysis results between TyG index and HbA1c, it was determined that the values both before treatment and in the 3rd month of treatment showed a correlation r0.516, P0.001 and r0.448, P0.001, respectively. Conclusions: SGLT-2 inhibitor usage significantly reduces TyG index in diabetic patients, and new studies are needed to investigate the effect of these drugs on triglyceride index among pre-diabetic patients.

Makale detayları

Investigation of the effect of SGLT-2 inhibitors on the triglyceride/glucose index in diabetic patients: a cross-sectional study

Yazarlar:

Düriye Sıla Karagöz Özen | Abdulcelil Kayabaş | Rana İlhan Van | Mehmet Derya Demirağ

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Internal Diseases

Dergi:

The European Research Journal Vol.11 Issue 3, pp.449-455

Belge Tipi:

Makale

Yayın Tarihi:

4/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001345449

pISSN:

2149-3189

Triglyceride glucose index

SGLT-2 inhibitor

dapagliflozin

empagliflozin

diabetes mellitus

Sayı

Makale detayları

Investigation of the effect of SGLT-2 inhibitors on the triglyceride/glucose index in diabetic patients: a cross-sectional study

Yazarlar: Düriye Sıla Karagöz Özen | Abdulcelil Kayabaş | Rana İlhan Van | Mehmet Derya Demirağ

Yayıncı: Prusa Medical Publishing

Ana Başlıklar: Internal Diseases

Dergi: The European Research Journal Vol.11 Issue 3, pp.449-455

Belge Tipi: Makale

Yayın Tarihi: 4/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001345449

pISSN: 2149-3189

Triglyceride glucose index

SGLT-2 inhibitor

dapagliflozin

empagliflozin

diabetes mellitus

Sayı

Yazarlar:

Düriye Sıla Karagöz Özen | Abdulcelil Kayabaş | Rana İlhan Van | Mehmet Derya Demirağ

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Internal Diseases

Dergi:

The European Research Journal Vol.11 Issue 3, pp.449-455

Belge Tipi:

Makale

Yayın Tarihi:

4/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001345449

pISSN:

2149-3189